Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
IgA Nephropathy: early-phase trial registry
3 of 11 indexed IgA Nephropathy trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,577 of 28,707 conditions by registered trial count.
11 US clinical trials · 3 currently recruiting · #1,577 of 28,707 conditions by registered trial count
IgA Nephropathy: 11 US clinical trials tracked, 3 recruiting.
IgA Nephropathy is the subject of 11 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 4 are in Phase 3-4 (later-stage) and 7 in Phase 1-2 (earlier-stage). The most active sponsor is Novartis Pharmaceuticals, running 3 of these trials.
Enrollment posture brief
Registry condition iga-nephropathy
OPEN 3 | RECR 27% | LATE 4 | EARLY 7 | RANK #1577 | SPON 3
Volume-matched condition peers
Nearest open-share peer: Atherosclerotic Cardiovascular Disease (27% recruiting · 22 trials)
IgA Nephropathy lists 3 open slots (27% of 11 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for IgA Nephropathy on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
IgA Nephropathy is recruiting below its size-band peers.
3 of 11 indexed trials (27.3%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates IgA Nephropathy research.
Novartis Pharmaceuticals accounts for 3 of 11 trials (27.3%). 9 distinct sponsors appear on at least one study for this condition label.
-
Typical IgA Nephropathy enrolment sits around 103 participants.
Median target enrolment is 103 among the 11 trials that report a genuine target (sentinel values excluded). 5 of those (45.5%) plan for fewer than 100 participants.
-
IgA Nephropathy research is mostly interventional.
11 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
11 total, page 1 of 1
Efficacy and Safety of Extended TARPEYO® Treatment Beyond 9 Months in Adult Patients With Primary IgA Nephropathy
Calliditas Therapeutics AB
NCT06712407
Trial of the Impact of Sibeprenlimab on Immunoglobulin A Nephropathy Kidney Tissue
Otsuka Pharmaceutical Development & Commercialization
NCT06740526
Study of BHV-1400 in IgA Nephropathy
Biohaven Therapeutics
NCT07054684
Atrasentan in Patients With IgA Nephropathy
Chinook Therapeutics
NCT04573478
A Study of Zigakibart in Adults With IgA Nephropathy
Novartis Pharmaceuticals
NCT05852938
Atacicept in Subjects With IgA Nephropathy
Vera Therapeutics
NCT04716231
Atrasentan in Patients With Proteinuric Glomerular Diseases
Novartis Pharmaceuticals
NCT04573920
Safety and Tolerability of BION-1301 in Healthy Volunteers and Adults With IgA Nephropathy (IgAN)
Novartis Pharmaceuticals
NCT03945318
A Phase 2 Trial of the Safety and Efficacy of Bardoxolone Methyl in Patients With Rare Chronic Kidney Diseases - PHOENIX
Biogen
NCT03366337
Safety and Efficacy Study of Fostamatinib to Treat Immunoglobin A (IgA) Nephropathy
Rigel Pharmaceuticals
NCT02112838
Phase II Study Assessing Safety and Efficacy of APL-2 in Glomerulopathies
Apellis Pharmaceuticals
NCT03453619
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 5 |
| Phase 3 | 3 |
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on IgA Nephropathy records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on IgA Nephropathy trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this IgA Nephropathy page
11 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 3 IgA Nephropathy trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Novartis Pharmaceuticals sponsors the most IgA Nephropathy trials on record, review their full trial history before evaluating a specific study. See Novartis Pharmaceuticals's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This IgA Nephropathy condition card totals 11 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.